Ribavirin: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Jamie Costa (talk | contribs) No edit summary |
Jamie Costa (talk | contribs) No edit summary |
||
| Line 24: | Line 24: | ||
# Chung, R.T., Gale, M.J., Polyak, S.J., Lemon, S.M., Liang, T.J., & Hoofnagle, J.H. (2008). Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology, 47 (1), 306-320. doi: 10.1002/hep.22070 | # Chung, R.T., Gale, M.J., Polyak, S.J., Lemon, S.M., Liang, T.J., & Hoofnagle, J.H. (2008). Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology, 47 (1), 306-320. doi: 10.1002/hep.22070 | ||
# Paeshuyse, J, Dallmeier, K, Neyts, J. (2011). Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Current Opinion in Virology. 1(6): 590-598. doi: 10.1016/j.coviro.2011.10.030 | # Paeshuyse, J, Dallmeier, K, Neyts, J. (2011). Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Current Opinion in Virology. 1(6): 590-598. doi: 10.1016/j.coviro.2011.10.030 | ||
# Foster, G. (2010). Pegylated interferons for the treatment of chronic Hepatitis C. Drugs. 70(2):147-165. doi:10.2165/11531990-000000000-00000 | |||
# National Heart, Lung and Blood Institute. (2016, September 26). Pneumonia. Retrieved from https://www.nhlbi.nih.gov/health/health-topics/topics/pnu | # National Heart, Lung and Blood Institute. (2016, September 26). Pneumonia. Retrieved from https://www.nhlbi.nih.gov/health/health-topics/topics/pnu | ||
